Isofol receives recommendation from iDSMB to complete the global Phase III AGENT study for market registration as planned with 440 patients
GOTHENBURG, Sweden, March 19, 2021 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announces that the independent Data Safety and Monitoring Board (iDSMB) has recommended continuation of the global Phase III AGENT study with 440 patients, in accordance with the study design for the drug candidate, arfolitixorin. Isofol expects the top line results for the AGENT study to be available during H1 2022.The iDSMB recommendation follows a pre-scheduled interim analysis as part of the study design and was initiated when the 330[th] patient had been treated